title: Serum biomarker analysis of collagen disease patients with acute-onset diffuse interstitial lung disease.
abstract: BACKGROUND
  Interstitial lung disease (ILD) is frequently associated with collagen diseases. The prognosis of acute-onset diffuse ILD (AoDILD) occurring in collagen disease patients is very poor. Here, we investigated serum biomarker profiles of AoDILD to find markers predicting outcome in patients with collagen diseases.
  
  
  METHODS
  A solid-phase antibody array was used for screening 274 biomarkers in pooled sera from collagen disease patients in the AoDILD state and in the stable state. Biomarkers in individual sera were detected without pooling by bead-based immunoassay.
  
  
  RESULTS
  The serum levels of matrix metalloproteinase (MMP)-1, tissue inhibitor of metalloproteinase (TIMP)-1, osteopontin, interleukin (IL)-2 receptor α (IL-2Rα), and IL-1 receptor antagonist were significantly increased in AoDILD, but TIMP-2, MMP-3, and eotaxin 2 levels were decreased. The MMP-3 to MMP-1 ratio was reduced in AoDILD state. This tendency was also observed in RA patients with AoDILD. Moreover, serum IL-6 level was significantly increased in the AoDILD state in patients with acute exacerbation of ILD (AE-ILD). Serum TIMP-1 and IL-2Rα levels were significantly increased in the AoDILD state in patients with drug-induced ILD (DI-ILD), whereas TIMP-2, MMP-3, and eotaxin 2 levels were decreased. The MMP-3 to MMP-1 ratio was reduced in AoDILD state in patients with DI-ILD. The serum TIMP-3, MMP-9, osteopontin, IL-2Rα, MMP-1, and MMP-8 levels were significantly increased in the AoDILD state in patients who subsequently died, whereas TIMP-2 and MMP-3 levels were decreased in those who survived. The MMP-3 to MMP-1 ratio was reduced in AoDILD state in patients who died, but not in those who survived.
  
  
  CONCLUSIONS
  Serum biomarker profiles could represent prognosis markers for AoDILD in collagen diseases.
authors: Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, 18-1 Sakuradai, Minami-ku, Sagamihara, Kanagawa, 252-0392, Japan.
authors: Shomi
authors: S
authors: Oka
authors: Hiroshi
authors: H
authors: Furukawa
authors: Kota
authors: K
authors: Shimada
authors: Hiromi
authors: H
authors: Hayakawa
authors: Naoshi
authors: N
authors: Fukui
authors: Naoyuki
authors: N
authors: Tsuchiya
authors: Shigeto
authors: S
authors: Tohma
mesh_terms: D000208:Acute Disease; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000097:blood; D015415:Biomarkers / Q000097:blood; D003095:Collagen Diseases / Q000097:blood*; D016207:Cytokines / Q000097:blood; D018450:Disease Progression; D005260:Female; D006801:Humans; D007118:Immunoassay; D017563:Lung Diseases, Interstitial / Q000097:blood*; D008297:Male; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D016207:Cytokines